盐酸替罗非班在急性心肌梗死患者介入治疗中的应用

目的探讨盐酸替罗非班在急性心肌梗死(AMI)患者经皮冠状动脉介入(PCI)治疗中的应用价值。方法 74例AMI患者分为观察组42例和对照组32例,对照组患者给予常规治疗,观察组在常规治疗的基础上给予盐酸替罗非班。观察2组患者出血事件、左心室射血分数(LVEF)、左心室舒张末期容积指数(LVEDVI)、左心室收缩末期容积指数(LVESVI)及主要心脏不良反应。结果 2组出血率比较差异无统计学意义(P>0.05);观察组血小板减少症发生率低于对照组(P<0.05)。术后1个月观察组LVEF、LVEDVI及LVESVI较对照组明显改善(P<0.05);术后3个月2组患者LVEF、LVEDVI及LVESVI比较差异无统计学意义(P>0.05)。观察组患者主要心脏不良反应事件发生率低于对照组(P<0.05)。结论盐酸替罗非班可有效改善行PCI治疗患者的心功能,抗血小板聚集,减少出血、血小板减少症及主要心脏不良反应事件的发生。

Application of tirofiban hydrochloride in patients with acute myocardial infarction by interventional therapy

Objective To explore the value of tirofiban hydrochloride in patients with acute myocardial infarction(AMI) by percutaneous coronary intervention(PCI).Methods Seventy-four patients with AMI were divided into observation group(n=42) and control group(n=32),the patients in control group were treated with conventional therapy,based on this,the patients in observation group were treated with tirofiban hydrochloride.The bleeding events,left ventricular ejection fraction(LVEF),left ventricular end-diastolic volume index(LVEDVI),left ventricular end-systolic volume index(LVESVI) and main adverse effect of heart were observed in two groups.Results There was no statistical difference in the rate of bleeding between two groups(P>0.05).The incidence rate of thrombocytopenia in observation group was lower than that in control group(P<0.05).Compared with control group,LVEF,LVEDVI and LVESVI were improved obviously in observation group one month after operation(P<0.05).Three months after operation,there was no statistical difference in LVEF,LVEDVI and LVESVI between two groups(P>0.05).The incidence rate of main adverse effect of heart in observation group was lower than that in control group(P<0.05).Conclusion Tirofiban hydrochloride can effectively improved the heart function,prevent platelet aggregation,decrease the incidence rates of bleeding,thrombocytopenia and main adverse effect of heart in patients underwent PCI.